Editorial Note: This article is an internal production sample used exclusively for contributor outreach. All content, author bios, and associated data are strictly illustrative and fictional.
Most of the cancers that kill Americans have no routine screening test. We can screen for breast, colorectal, cervical, and, in high-risk smokers, lung cancer. Pancreatic, ovarian, liver, and esophageal cancers are usually found only after symptoms appear, and by then they have often spread.
That gap is why multi-cancer early detection (MCED) blood tests have drawn so much attention, and why this week matters. On September 23, 2026, an FDA advisory committee is meeting in open session to discuss and vote on the premarket approval application for the Galleri test from GRAIL, Inc. No blood test that screens for multiple cancers has yet passed the FDA's safety and accuracy review.
